#1 Clinical Trials Search in Europe

Gsk3915393

Clinical trials are investigating Gsk3915393 in people with idiopathic pulmonary fibrosis (IPF), a long-term lung disease that causes scarring. These studies aim to evaluate how well Gsk3915393 works and how safe it is, mainly in adults with IPF. The main trial listed is a phase 2 study comparing Gsk3915393 with placebo.

Table of Contents

Clinical trial overview

The available clinical trial data show one study of Gsk3915393 in people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and can make breathing harder over time.[1]

This study is a phase 2 trial, which means it is testing whether the treatment may help and continuing to check safety in a group of patients with the disease.[1]

The study is listed as completed and included 150 participants.[1]

Study design and treatment groups

The trial is an interventional study, which means researchers gave a study treatment and then measured what happened.[1]

Participants were assigned to receive either Gsk3915393 or a placebo that matched the tablet.[1]

A placebo looks like the study medicine but does not contain the active treatment, so it helps researchers compare results in a fair way.[1]

Who can participate

The study was designed for participants with idiopathic pulmonary fibrosis.[1]

The source data do not provide more detailed entry rules, such as age limits, lung test requirements, or other medical conditions that were allowed or excluded.[1]

What the trial measures

The main outcome was the absolute change from baseline in FVC (mL) at Week 26.[1]

FVC, or forced vital capacity, is the amount of air a person can breathe out strongly after taking a deep breath.[1]

Baseline means the starting measurement before treatment begins, and Week 26 is the study visit after 26 weeks of treatment and follow-up.[1]

The brief study summary says the main goal was to see whether Gsk3915393 could reduce the decline in lung volume in people with IPF compared with placebo.[1]

What these results mean for patients

This trial focused on whether Gsk3915393 may help protect lung function in people living with IPF.[1]

Because the study was phase 2, it was designed to learn more about possible benefit and safety rather than to give a final answer for routine care.[1]

Only one trial was provided in the source data, so the current trial picture for Gsk3915393 is limited to this completed study in IPF.[1]

Trial ID Phase Condition studied Status Enrollment
NCT06317285 Phase 2 Idiopathic Pulmonary Fibrosis Completed 150

FAQ

  • What is Gsk3915393 being studied for in clinical trials? It is being studied in idiopathic pulmonary fibrosis (IPF), a disease that causes scarring in the lungs. The trial looks at whether Gsk3915393 can help reduce the decline in lung function.
  • Who can take part in the trial? The listed study includes participants with idiopathic pulmonary fibrosis. The trial data do not give more detailed eligibility rules in the source provided.
  • What phase is the Gsk3915393 trial? The listed study is a phase 2 trial. Phase 2 studies usually look more closely at whether a treatment may work and continue to check safety.
  • What is the main result the trial is measuring? The main outcome is the change in forced vital capacity, or FVC, at week 26. FVC is the amount of air a person can forcefully breathe out after taking a deep breath.
  • Is the trial comparing Gsk3915393 with another treatment? Yes. The study compares Gsk3915393 with a placebo that matches the tablet. A placebo looks like the study medicine but does not contain the active treatment.

Ongoing Clinical Trials on Gsk3915393

  • Study on the Effects of GSK3915393 for Patients with Idiopathic Pulmonary Fibrosis

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Poland Spain

Glossary

  • Idiopathic Pulmonary Fibrosis (IPF): A long-term lung disease that causes scarring in the lungs. This scarring can make breathing harder over time.
  • Phase 2: A middle stage of clinical research. It helps researchers learn more about whether a treatment may work and how safe it is.
  • Placebo: A look-alike treatment that does not contain the active study medicine. It is used to compare results fairly.
  • Interventional study: A type of clinical trial where researchers give a treatment and then measure what happens.
  • Efficacy: How well a treatment works for the condition being studied.
  • Safety: Information about how well a treatment is tolerated and whether it causes problems.
  • Forced vital capacity (FVC): The amount of air a person can breathe out strongly after taking a deep breath. It is a common test of lung function.
  • Baseline: The starting point before treatment begins. Results are often compared with this first measurement.
  • Week 26: A study time point 26 weeks after the start of the trial, used to measure changes over time.
  • Enrollment: The number of people planned or included in a study.

References